Estrogen News and Research

Latest Estrogen News and Research

Antiestrogen supplements may reduce risk of melanoma in women with breast cancer

Women with breast cancer who take antiestrogen supplements may be decreasing their risk for melanoma, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

5 Jan 2012

Four or more coffees reduce risk of womb cancer

According to a new study drinking four or more cups of coffee a day may reduce risk of developing endometrial cancer or womb cancer by almost 25 per cent.

1 Jan 2012

Oncologists present results from studies on relapse of breast cancer

The University of Kentucky Markey Cancer Center breast oncologist Dr. Suleiman Massarweh and his research team presented findings from their studies on relapse of breast cancer at the San Antonio Breast Cancer Symposium this month.

26 Dec 2011

Oak Pharmaceuticals acquires three Lundbeck hospital-based injectables

Akorn, Inc., a niche generic pharmaceutical company, today announced that its wholly-owned subsidiary, Oak Pharmaceuticals, has acquired three off-patent, branded, hospital-based injectables from the US subsidiary of H. Lundbeck A/S.

23 Dec 2011

Smoking in women associated with skin cancer: Study

A new study has found a link between tobacco use and skin cancer especially in women. The study found that women who had squamous cell skin cancer were more likely to have smoked than those who were free from the disease. And those who smoked at least 20 years were twice as likely to develop squamous cell skin cancer - a less aggressive form of skin cancer as melanoma.

19 Dec 2011

Researchers discover miR-520 blocks cancer-promoting signaling pathway

MicroRNAs or miRNAs are tiny RNA molecules that have only about 20 nucleotides and do not code for proteins. They regulate many important processes in cells by binding to target messenger RNAs - the instructions for protein production -, thus blocking production of the respective protein. In cancer, the production of some miRNAs is often reduced or amplified. This particularly affects miRNAs that regulate the activity of cancer-promoting genes.

17 Dec 2011

Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types

Synta Pharmaceuticals Corp. Ganetespib shows potent in vitro and in vivo activity against multiple types of breast cancer including HER2-positive, ER/PR positive, triple-negative, and inflammatory breast cancer according to results presented at the San Antonio Breast Cancer Symposium.

13 Dec 2011

Bone drug effective in improving breast cancer survival

In a chance finding a bone drug was found to be effective in breast cancer. While doctors were prescribing young women a medicine to keep their bones strong during breast cancer treatment they noted that after seven years it did more than that - the bone drug improved survival, as much as most chemotherapy could do.

12 Dec 2011

Obese women with early-stage HER2-positive breast cancer may have poorer outcomes

Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight, Mayo Clinic researchers found in a study presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth.

12 Dec 2011

HER2 proteins do not predict breast cancer patient's outcome after Herceptin treatment

Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer with Herceptin, say Mayo Clinic researchers.

12 Dec 2011

Many postmenopausal women quit breast cancer drugs early because of side effects

Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves -- as well as the largest, most scientifically rigorous study to examine the question -- reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.

12 Dec 2011

MRI can predict breast cancer prognosis

Quantitative magnetic resonance imaging measures were associated with prognostic tumor markers, demonstrating the potential of magnetic resonance imaging for prediction of disease prognosis and stratification of patients to appropriate therapies, according to preliminary data presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

9 Dec 2011

Women with non-melanoma skin cancers more likely to have smoked cigarettes

Women who have non-melanoma skin cancers are more likely to have smoked cigarettes compared to women without skin cancer, said researchers at Moffitt Cancer Center in Tampa, Fla., who published study results in a recent issue of Cancer Causes & Control.

9 Dec 2011

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.

9 Dec 2011

Breast cancer risks and management updates

A new report that looks at the environmental factors that affect risk of breast cancer is out. It suggests that women can reduce their risk by avoiding unnecessary medical radiation, forgoing hormone treatments for menopause that combine estrogen and progestin, limiting alcohol intake and minimizing weight gain.

8 Dec 2011

Heart patients may experience fewer traumas with new invention

Heart patients may experience "a lot less" trauma with a new invention to mend leaky valves with minimum cutting, says inventor James Gammie, MD, an associate professor at the University of Maryland (UM) School of Medicine.

8 Dec 2011

Combination of two anti-estrogen drugs extends survival time of women with breast cancer

Post-menopausal women with hormone receptor-positive metastatic breast cancer may have a new treatment option that could lengthen their lives, according to results of a study by the SWOG clinical trials network that were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.

8 Dec 2011

Estrogen News and Research

Latest Estrogen News and Research

Antiestrogen supplements may reduce risk of melanoma in women with breast cancer

Four or more coffees reduce risk of womb cancer

Oncologists present results from studies on relapse of breast cancer

Oak Pharmaceuticals acquires three Lundbeck hospital-based injectables

Smoking in women associated with skin cancer: Study

Researchers discover miR-520 blocks cancer-promoting signaling pathway

Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types

Bone drug effective in improving breast cancer survival

Obese women with early-stage HER2-positive breast cancer may have poorer outcomes

HER2 proteins do not predict breast cancer patient's outcome after Herceptin treatment

Many postmenopausal women quit breast cancer drugs early because of side effects

MRI can predict breast cancer prognosis

Women with non-melanoma skin cancers more likely to have smoked cigarettes

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Breast cancer risks and management updates

Heart patients may experience fewer traumas with new invention

Combination of two anti-estrogen drugs extends survival time of women with breast cancer

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Notch inhibitor appears to treat breast cancer

Combination treatment extends lives of women with metastatic breast cancer

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Estrogen News and Research

Latest Estrogen News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in